Table 2.

Main Adverse Events Reported in Tofacitinib Groups During Phase 3 Trials (Ref 36)

Adverse Events	%
Any infection	26%
Nasopharyngitis	7.7%
Herpes Zoster	1.4%
Serious infections	0.8%
Headache	7.2%
Arthralgia	4.5%
Cardiovascular events	0.5%
Non-melanoma skin cancers	0.4%
Abnormal laboratory test results*
Hypercholesterolemia	19.3%
Hypertriglyceridemia	3.9%
Rise in creatine kinase levels	13.5%

Note: *Laboratory data were missing for some patients in the original work.